Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase
Linda Morrow, Douglas B Muchmore, Marcus Hompesch, Elizabeth A Ludington, Daniel E Vaughn, Linda Morrow, Douglas B Muchmore, Marcus Hompesch, Elizabeth A Ludington, Daniel E Vaughn
Abstract
Objective: To compare the pharmacokinetics and glucodynamics of three rapid-acting insulin analogs (aspart, glulisine, and lispro) injected subcutaneously with or without recombinant human hyaluronidase (rHuPH20).
Research design and methods: This double-blind six-way crossover euglycemic glucose clamp study was conducted in 14 healthy volunteers. Each analog was injected subcutaneously (0.15 units/kg) with or without rHuPH20.
Results: The commercial formulations had comparable insulin time-exposure and time-action profiles as follows: 50% exposure at 123-131 min and 50% total glucose infused at 183-186 min. With rHuPH20, the analogs had faster yet still comparable profiles: 50% exposure at 71-79 min and 50% glucose infused at 127-140 min. The accelerated absorption with rHuPH20 led to twice the exposure in the first hour and half the exposure beyond 2 h, which resulted in 13- to 25-min faster onset and 40- to 49-min shorter mean duration of insulin action.
Conclusions: Coinjection of rHuPH20 with rapid-acting analogs accelerated insulin exposure, producing an ultra-rapid time-action profile with a faster onset and shorter duration of insulin action.
Trial registration: ClinicalTrials.gov NCT00979875.
Figures
References
- Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med 1997;337:176–183
- Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641–659
- Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008;47:7–20
- Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174–183
- Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337–1344
- Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459–469
- Rassam AG, Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 1999;22:133–136
- Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Tech 2010;4:419–428
- Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427–440
- Vaughn DE, Yocum RC, Muchmore DB, et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009;11:345–352
- Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther 2011;13:1039–1045
- Heinemann L, Anderson JH., Jr Measurement of insulin absorption and insulin action. Diabetes Technol Ther 2004;6:698–718
- US FDA Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products–general considerations. Available at Accessed 26 April 2012
- Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011;34:666–668
- Hompesch M, Muchmore DB, Morrow L, Ludington EA, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther 2012;14:218–224
Source: PubMed